Response to the Letter Regarding "Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Induced by Meropenem in a Patient Under Therapy With Avelumab and Subsequent Flare-up".
J Investig Allergol Clin Immunol
2026
36
1
83-84
Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study.
Br J Dermatol
2026
194
1
77-85
Assessing Skin Barrier Integrity: A Comparative Study Using Transepidermal Water Loss, Electrical Impedance Spectroscopy and Corneometry.
Contact Dermatitis
2026
94
4
327-337
Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
Paediatr Drugs
2026
28
3
307-320
Inpatient Penicillin Allergy Evaluation-Skin Testing Versus Direct Oral Challenge?
J Allergy Clin Immunol Pract
2026
14
5
1050-1057
Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria.
Allergy
2026
81
7
2391-2402
Neutralizing IL-22RA1 improves histologic and molecular alterations associated with atopic dermatitis pathogenesis.
J Allergy Clin Immunol
2026
157
3
653-665
[Current dermatology guidelines in Germany: a selection of clinically relevant recommendations].
Dermatologie (Heidelb)
2026
77
1
23-29
Letter to the Editor-Re: Sabouraud-Leclerc D, Mariotte D, Bradatan E, et al. Food Anaphylaxis: Eight Food Allergens Without Mandatory Labelling Highlighted by the French Allergy-Vigilance Network. Clinical and Experimental Allergy. 2025;0:1-8. Doi: 10.1111/cea.70130.
Clin Exp Allergy
2026
56
1
115-116